Pharma Market Access Insights - from Petauri Evidence
Petauri Evidence
65 episodes
1 month ago
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market? In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges. ...
All content for Pharma Market Access Insights - from Petauri Evidence is the property of Petauri Evidence and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market? In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges. ...
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market?In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges.We ...
How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison?Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Access) shares some of the challenges that our clients face when developing HTA-ready health economic models with limited clinical trial data. Joseph O’Reilly (Princip...
How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months?In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon ICS) to explore these challenges.Jo and Karen discuss:How ICBs and Directors of Commissioning prepare for winter pressuresThe current key areas of focus at Pla...
Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispers and NHS Whispers came together, to bring you an overarching view of what it takes to access the NHS with a medtech or pharmaceutical innovation.Guest speaker Dr Faris Al-Ramadani who shared his experience of introducing new technologies to the NHS fr...
What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25?In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) spoke to a panel of NHS Associates about the current state and future of primary care and what this means for industry. Our panellists were:- Jack Wagstaf...
Discover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves as a trusted partner. Watch this 20-minute discussion between Iain Shield (Associate Director – Market Access) and Ben Spurr (Head of Partnerships) to discover how...
What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The University of Ottawa).We take a look at the market access, health policy, and health technology assessment in Canada. Clare Foy and Don Husereau explore:The m...
Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have you explored opportunities in growth markets, such as those in the Middle East and North Africa (MENA) region?In this webinar, our Global Market Access tea...
Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders?We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion that explored finance, funding flows, system priorities, and the decision-making process in NHS Regions.Richard heads up system co-ordination work across the NHS So...
What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation?Host Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by guest speakers Debbie Morgan (Director of Service Improvement and Transformation, Cambridge University Hospitals NHS Fo...
What is health economic evaluation and which modelling approaches can be used to support market access activities?In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) and Daniel MacDonald (Associate Consultant – Health Economics) de-mystify the different approaches to health economic modelling.Our specialists explore six of the mo...
Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies.Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) route be appropriate for your product? What will payers, HTA agencies, and other key decision makers be looking for? And how should this information be presented?I...
How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market.Clare Foy (Director – Global Market Access, Mtech Access) speaks to Janice MacLennan (Pharma and Medtech brand strategist and founder of NMBLR) about how market access, HEOR and commercialisation leads in Pharma and Medtech can best s...
What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024.Malcolm Qualie and David Thorne explored:Specialised commissioning ...
What does it take to run a truly patient-centric integrated health system? What does the Welsh journey with integration tell us about the future for England?Paul Mears (CEO, Cwm Taf Morgannwg University Health Board) joins Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) to explore the integrated care model in Wales and the lessons England can take from the Welsh experience.In this NHS Whispers webinar, guest speaker Paul Mears shares his experiences leading a Wel...
Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA).We explore:- The nature of the Italian market and the reimbursement process- Pricing and market access considerations when launching in Italy- What the reforms at AIFA mean for market...
Dr Farzana Hussain (GP Principal, The Project Surgery) and Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) explore the unmet needs of Primary Care Networks (PCNs) and how industry can best support primary care leaders and GPs as we head into winter, 2024 and beyond.Former ‘GP of the year’ and strategic influencer over primary care policy, Dr Farzana Hussain, discusses the unmet needs in primary care, how primary care leaders are responding to these challenges, and whe...
How can our community support NHS leaders to deliver a data-led, people-centric health service?Dr Mark Davies (Global Chief Health Officer, IBM) joins Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) to explore the power of data, the role of community and how the health and life sciences ecosystem can support the NHS’s population health management goals.Population health management has the potential to be a powerful tool for healthcare systems, effecting the way health...
How is Artificial Intelligence being used in the development of new medicines? What role can AI currently play in clinical trials? Where can AI bridge gaps and solve challenges? What could this mean for the future of market access?In this webinar, Dr George Magrath explains how his team at Lexitas are using AI in clinical trials in the field of ophthalmology. George and Calum explore:- How, when and where AI is being used in clinical trials- How Lexitas are using AI in clinical trials for oph...
How is the UK political landscape evolving and what does this mean for Health Technology and Medical Device innovators?Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) speaks to William Lee (Head of Policy and Compliance, British Healthcare Trades Association [BHTA]) about health policy, regulation and its implications for Medtech, Health technologies, and Medical Device market access.With the challenges of the pandemic and the changes brought in following Brexit,...
Pharma Market Access Insights - from Petauri Evidence
What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market? In this episode, Clare Foy (Director – Global Market Access, Mtech Access) interviews colleagues Nicole Lodowski (Managing Director, Petauri Evidence) and Bob Nordyke (Senior Advisor, Petauri Evidence) about US payer evidence challenges. ...
